Pegtibatinase
- Generic Name
- Pegtibatinase
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 3G3529LUQ7
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥12 to ≤65 Years of Age with Classical Homocystinuria (HCU)
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06431893
- Locations
- 🇺🇸
Travere Investigational Site - Virtual Site, Culver City, California, United States
🇺🇸Travere Investigational Site, Philadelphia, Pennsylvania, United States
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06247085
- Locations
- 🇺🇸
Travere Investigational Site - Virtual Site, Culver City, California, United States
Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)
- First Posted Date
- 2018-01-23
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Travere Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03406611
- Locations
- 🇺🇸
Travere Investigational Site, Philadelphia, Pennsylvania, United States
🇺🇸Travere Investigational Site - Virtual Site, Culver City, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath